Skip to content
Open access

Comparative prognostic value of CKD risk strata in HFpEF/HFmrEF: insights from TOPCAT

Sep 2026 · Scientific Reports · 0 citations

TL;DR

The KDIGO risk classification provided prognostic information at least comparable to individual or simply unweighted renal metrics, and its clinical value lies in offering a convenient, guideline-aligned, single integrated score for routine bedside use and raising more attention to isolated UACR elevation.

Abstract

Chronic kidney disease (CKD) worsens prognosis in heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). Estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) capture distinct aspects of kidney disease and are independently linked to HF progression. The KDIGO framework recommended combination of both, but its incremental prognostic value in HFpEF/HFmrEF has not been systematically evaluated. We compared KDIGO risk strata against conventional renal metrics for major adverse outcomes. This post-hoc analysis of the TOPCAT trial categorized 1173 patients with HF with LVEF ≥ 45% (encompassing HFpEF and HFmrEF) into 2024 KDIGO risk strata. The associations between renal metrics (KDIGO classification, CKD stage, UACR, and continuous eGFR) and a primary composite endpoint of cardiovascular death, aborted cardiac arrest and heart failure hospitalization were assessed using Lasso‑Cox regression with 10‑fold cross‑validation, which effectively selected the most relevant variables and avoided overfitting. Model discrimination and incremental predictive value were evaluated via C-statistic, Brier score, IDI and NRI. Among 1173 patients with HFpEF/HFmrEF, the distribution across KDIGO risk categories was: Low 29.5% ( n  = 346), Moderate 33.1% ( n  = 388), High 23.3% ( n  = 273), and Very High 14.1% ( n  = 166). A graded increase in risk was observed across advancing KDIGO categories, with the Very High-risk group exhibiting a substantially elevated hazard for the primary endpoint (fully adjusted HR 1.980; 95% CI [1.260, 3.109]; p  = 0.003) and HF hospitalization (HR 3.039; 95% CI [1.975, 4.652]; p  < 0.001). When added to the basic clinical model, KDIGO stratification demonstrated significant incremental predictive value for the primary endpoint (IDI: 0.004, p  = 0.032; NRI: 0.068, p  = 0.032), with particularly consistent improvements for heart failure hospitalization. The KDIGO risk classification provided prognostic information at least comparable to individual or simply unweighted renal metrics. Although its statistical incremental gains were modest, its clinical value lies in offering a convenient, guideline-aligned, single integrated score for routine bedside use and raising more attention to isolated UACR elevation.

Read PDF

Similar papers

Nov 2026

Abstract 6518: Kidney Failure Risk Equation, Clinical Outcomes, and Effect of Finerenone in HFmrEF/HFpEF: Insights from FINEARTS-HF

Background: The Kidney Failure Risk Equation (KFRE) is recommended in international guidelines for estimating the risk of kidney failure in patients with chronic kidney disease (CKD). The prognostic relevance of the KFRE has not been described in patients with heart failure and mildly reduced or preserved ejection f...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Oct 2026

NT-proBNP and UACR for outcome prediction in HFrEF

NTproBNP is the central biomarker for risk stratification in heart failure with reduced ejection fraction (HFrEF). The urinary albumin-to-creatinine ratio (UACR) reflects renal and microvascular injury, but its independent and incremental prognostic value beyond NTproBNP remains uncertain. To evaluate the...

N. Panagiotides, S. Prausmueller, H. Arfsten et al. · 0 citations
Open access Oct 2026

Prognostic impact of chronic kidney disease and renal safety of contemporary therapies in patients with heart failure: a real-world analysis

Chronic kidney disease (CKD) is common in heart failure (HF) and is associated with adverse outcomes. However, its prognostic impact and the effects of contemporary HF therapies—including angiotensin receptor–neprilysin inhibitors (ARNI) and sodium–glucose cotransporter-2 inhibitors (SGLT2i)—on renal function rem...

E. Tartaglia, N. Bonini, M. Mantovani et al. · 0 citations
Open access Oct 2026

Distribution and clinical utility of the kidney disease improving global outcomes chronic kidney disease risk classification in patients undergoing atrial fibrillation ablation

Chronic kidney disease (CKD) is a key component of the cardiovascular–kidney–metabolic (CKM) framework. However, in patients undergoing atrial fibrillation (AF) ablation, the distribution of CKD across Kidney Disease: Improving Global Outcomes (KDIGO) risk categories and its prognostic value remain unclear....

H. Ishiguchi, Y. Yoshiga, S. Hashimoto et al. · 0 citations
Open access Nov 2026

Development and external validation of a nomogram incorporating the TyG index and prognostic nutritional index for predicting cardiovascular events in patients with heart failure with preserved ejection fraction and chronic kidney disease

Heart failure with preserved ejection fraction (HFpEF) frequently coexists with chronic kidney disease (CKD), representing a high-risk cardiorenal phenotype within the cardiovascular–kidney–metabolic (CKM) syndrome. Despite the high burden of adverse cardiovascular events in this population, dedicated risk predicti...

Feng Wang, Chuan-Peng Wang, Rui-Hao Jiang et al. · 0 citations
Open access Oct 2026

Improving outcomes in HFpEF with advanced CKD: temporal trends from the SHEBAHEART Registry

Patients with advanced chronic kidney disease (CKD) and heart failure (HF) are systematically underrepresented in clinical trials despite comprising a substantial proportion of real-world HF populations [1]. Whether contemporary care has translated into improved outcomes in this high-risk group particularly among...

D. Hochstein, D. Sternik, V. Copeland et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.